A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

AstraZeneca agreed to partner two important oncology assets – Lynparza and selumetinib – with Merck after disappointing Imfinzi MYSTIC data. Merck will pay $1.6bn up front to get its hands on a PARP inhibitor, even though it previously owned one.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

AstraZeneca PLC agreed to partner two important oncology drugs with Merck & Co. Inc. after its PD-1 inhibitor Imfinzi (durvalumab) disappointed in a key trial, raising questions about whether the company ceded long-term earnings for a near-term win.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

Read the full article – start your free trial today!

More from Immuno-oncology

More from Anticancer